Liu Hangbing, Li Yi, Wang Yuli, Zhang Liying, Liang Xiaoqing, Gao Chunsheng, Yang Yang
Beijing Institute of Pharmacology and Toxicology, 100850, Beijing, People's Republic of China.
School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 110016, Shenyang, People's Republic of China.
Bioact Mater. 2025 Feb 13;47:481-501. doi: 10.1016/j.bioactmat.2025.01.021. eCollection 2025 May.
Red blood cells (RBCs), often referred to as "intelligent delivery systems", can serve as biological or hybrid drug carriers due to their inherent advantages and characteristics. This innovative approach has the potential to enhance biocompatibility, pharmacokinetics, and provide targeting properties for drugs. By leveraging the unique structure and contents of RBCs, drug-loading pathways can be meticulously designed to align with these distinctive features. This review article primarily discusses the drug delivery strategies and their applications that are informed by the structural and functional properties of the main components of RBCs, including living RBCs, membranes, hollow RBCs, and hemoglobin. Overall, this review article would assist efforts to make better decisions on optimization and rational utilization of RBCs derivatives-based drug delivery strategies for the future direction in clinical translation.
红细胞（RBCs）通常被称为“智能递送系统”，由于其固有的优势和特性，可作为生物或混合药物载体。这种创新方法有可能增强生物相容性、药代动力学，并为药物提供靶向特性。通过利用红细胞的独特结构和成分，可以精心设计药物负载途径，使其与这些独特特征相匹配。这篇综述文章主要讨论了基于红细胞主要成分（包括活红细胞、细胞膜、空心红细胞和血红蛋白）的结构和功能特性的药物递送策略及其应用。总体而言，这篇综述文章将有助于更好地决策，以优化和合理利用基于红细胞衍生物的药物递送策略，为未来临床转化指明方向。
